CDK4/6-话题@MedSci

#CDK4/6#

47篇内容 | 1998人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1490702, encodeId=839f1490e0254, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=EMBO Mol Med：化疗脱发？靶向药CDK4/6抑制剂或将带来防脱发新突破, objectType=article, longId=180007, objectId=c6d618000e24, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6d618000e24, replyNumber=0, likeNumber=70, createdTime=2019-09-26, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6d618000e24, moduleTitle=EMBO Mol Med：化疗脱发？靶向药CDK4/6抑制剂或将带来防脱发新突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6d618000e24)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490701, encodeId=56861490e0106, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=Sci transl med：MDM2拮抗剂可克服黑色素瘤对CDK4/6抑制剂的耐药性, objectType=article, longId=178015, objectId=77ed1e8015f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77ed1e8015f9, replyNumber=0, likeNumber=61, createdTime=2019-08-22, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77ed1e8015f9, moduleTitle=Sci transl med：MDM2拮抗剂可克服黑色素瘤对CDK4/6抑制剂的耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77ed1e8015f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490700, encodeId=0ed31490e00d2, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=NEJM：CDK4/6抑制剂联合内分泌疗法治疗晚期乳腺癌, objectType=article, longId=176285, objectId=ac241e628571, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac241e628571, replyNumber=0, likeNumber=106, createdTime=2019-07-28, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac241e628571, moduleTitle=NEJM：CDK4/6抑制剂联合内分泌疗法治疗晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac241e628571)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490699, encodeId=6013149069922, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=诺华的新型口服CDK4/6靶向抗癌药Kisqali喜获NICE推荐，用作二线治疗晚期乳腺癌, objectType=article, longId=175681, objectId=3cfe1e5681e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cfe1e5681e2, replyNumber=0, likeNumber=0, createdTime=2019-07-19, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cfe1e5681e2, moduleTitle=诺华的新型口服CDK4/6靶向抗癌药Kisqali喜获NICE推荐，用作二线治疗晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cfe1e5681e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490698, encodeId=f8071490698a0, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=CDK4/6抑制剂哌柏西利的上市给HR+乳腺癌的治疗带来改变, objectType=article, longId=175522, objectId=698d1e552260, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=698d1e552260, replyNumber=0, likeNumber=57, createdTime=2019-07-17, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=698d1e552260, moduleTitle=CDK4/6抑制剂哌柏西利的上市给HR+乳腺癌的治疗带来改变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=698d1e552260)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490697, encodeId=177c149069ee4, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=CDK4/6抑制剂哌柏西利成为HR+/HER2-晚期乳腺癌患者的新选择, objectType=article, longId=175253, objectId=ba771e52535a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba771e52535a, replyNumber=0, likeNumber=54, createdTime=2019-07-13, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba771e52535a, moduleTitle=CDK4/6抑制剂哌柏西利成为HR+/HER2-晚期乳腺癌患者的新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba771e52535a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490696, encodeId=e309149069679, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=郭宇教授：HR+晚期乳腺癌CDK4/6抑制剂进展后的治疗探索, objectType=article, longId=170145, objectId=dfb11e0145db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfb11e0145db, replyNumber=0, likeNumber=54, createdTime=2019-06-27, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfb11e0145db, moduleTitle=郭宇教授：HR+晚期乳腺癌CDK4/6抑制剂进展后的治疗探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfb11e0145db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490695, encodeId=98cf149069549, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=CDK4/6抑制剂在晚期乳腺癌治疗中的研究进展, objectType=article, longId=168145, objectId=b59a16814522, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b59a16814522, replyNumber=0, likeNumber=77, createdTime=2019-06-13, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b59a16814522, moduleTitle=CDK4/6抑制剂在晚期乳腺癌治疗中的研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b59a16814522)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490694, encodeId=688e149069467, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=2019ASCO：诺华的CDK4/6抑制剂Kisqali在III期晚期乳腺癌试验中提前到达终点, objectType=article, longId=167612, objectId=933416e61276, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=933416e61276, replyNumber=0, likeNumber=119, createdTime=2019-06-05, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=933416e61276, moduleTitle=2019ASCO：诺华的CDK4/6抑制剂Kisqali在III期晚期乳腺癌试验中提前到达终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=933416e61276)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490693, encodeId=5ab61490693af, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=CDK4/6抑制剂联合方案给HR+/HER2-乳腺癌患者带来的新希望, objectType=article, longId=167338, objectId=864316e338a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=864316e338a0, replyNumber=0, likeNumber=46, createdTime=2019-06-02, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=864316e338a0, moduleTitle=CDK4/6抑制剂联合方案给HR+/HER2-乳腺癌患者带来的新希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=864316e338a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490692, encodeId=78ed149069272, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=苏格兰SMC批准礼来的CDK4/6抑制剂abemaciclib，用于治疗晚期或转移性乳腺癌, objectType=article, longId=166117, objectId=2c7916611e50, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c7916611e50, replyNumber=0, likeNumber=73, createdTime=2019-05-16, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c7916611e50, moduleTitle=苏格兰SMC批准礼来的CDK4/6抑制剂abemaciclib，用于治疗晚期或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c7916611e50)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490691, encodeId=b1cc149069124, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=CDK4/6抑制剂联合内分泌一线治疗优势人群获益良多, objectType=article, longId=164704, objectId=fc20164e0485, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc20164e0485, replyNumber=0, likeNumber=78, createdTime=2019-04-22, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc20164e0485, moduleTitle=CDK4/6抑制剂联合内分泌一线治疗优势人群获益良多, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc20164e0485)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490690, encodeId=9e231490690b7, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=王涛教授：激素受体阳性晚期乳腺癌一线优先推荐CDK4/6抑制剂联合内分泌治疗, objectType=article, longId=164383, objectId=f363164383a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f363164383a2, replyNumber=0, likeNumber=54, createdTime=2019-04-18, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f363164383a2, moduleTitle=王涛教授：激素受体阳性晚期乳腺癌一线优先推荐CDK4/6抑制剂联合内分泌治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f363164383a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490689, encodeId=3a691490689ca, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=诺华的CDK4/6靶向性抑制剂Kisqali遭NICE拒绝，用于治疗晚期乳腺癌, objectType=article, longId=164062, objectId=b2ee164062f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2ee164062f7, replyNumber=0, likeNumber=49, createdTime=2019-04-12, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2ee164062f7, moduleTitle=诺华的CDK4/6靶向性抑制剂Kisqali遭NICE拒绝，用于治疗晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2ee164062f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490688, encodeId=1be21490688aa, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=CLIN CANCER RES：PI3K和CDK4/6联合抑制治疗PIK3CA突变肺鳞状细胞癌, objectType=article, longId=156162, objectId=125715616238, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=125715616238, replyNumber=0, likeNumber=67, createdTime=2018-12-21, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=125715616238, moduleTitle=CLIN CANCER RES：PI3K和CDK4/6联合抑制治疗PIK3CA突变肺鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=125715616238)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490687, encodeId=dda0149068ede, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=徐兵河教授：CDK4/6抑制剂在乳腺癌治疗中的价值, objectType=article, longId=151214, objectId=deb21512143c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=deb21512143c, replyNumber=0, likeNumber=69, createdTime=2018-10-18, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=deb21512143c, moduleTitle=徐兵河教授：CDK4/6抑制剂在乳腺癌治疗中的价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=deb21512143c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490686, encodeId=78b014906866c, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=CDK4/6抑制剂“三兄弟”，谁领风骚, objectType=article, longId=151213, objectId=8256151213d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8256151213d4, replyNumber=0, likeNumber=69, createdTime=2018-10-18, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8256151213d4, moduleTitle=CDK4/6抑制剂“三兄弟”，谁领风骚, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8256151213d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490685, encodeId=3b6d1490685ee, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=CSCO2018大家访谈录│王晓稼教授：内分泌+CDK4/6抑制剂还是化疗, objectType=article, longId=149675, objectId=8caf1496e50f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8caf1496e50f, replyNumber=0, likeNumber=64, createdTime=2018-09-28, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8caf1496e50f, moduleTitle=CSCO2018大家访谈录│王晓稼教授：内分泌+CDK4/6抑制剂还是化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8caf1496e50f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490684, encodeId=8de21490684d3, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=胡夕春教授：乳腺癌治疗新突破，CDK4/6抑制剂独领风骚！, objectType=article, longId=140525, objectId=33f81405254d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33f81405254d, replyNumber=0, likeNumber=75, createdTime=2018-06-13, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33f81405254d, moduleTitle=胡夕春教授：乳腺癌治疗新突破，CDK4/6抑制剂独领风骚！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33f81405254d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490683, encodeId=4ccd149068305, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=CLIN CANCER RES：肢端黑色素瘤CDK4通路基因改变表明CDK4/6抑制可以作为靶向疗法, objectType=article, longId=121178, objectId=6c591211e82d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c591211e82d, replyNumber=0, likeNumber=103, createdTime=2017-11-25, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c591211e82d, moduleTitle=CLIN CANCER RES：肢端黑色素瘤CDK4通路基因改变表明CDK4/6抑制可以作为靶向疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c591211e82d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CDK4/6

2020-05-29

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

EMBO Mol Med：化疗脱发？靶向药CDK4/6抑制剂或将带来防脱发新突破

2019-09-26

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

Sci transl med：MDM2拮抗剂可克服黑色素瘤对CDK4/6抑制剂的耐药性

2019-08-22

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

NEJM：CDK4/6抑制剂联合内分泌疗法治疗晚期乳腺癌

2019-07-28

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

诺华的新型口服CDK4/6靶向抗癌药Kisqali喜获NICE推荐，用作二线治疗晚期乳腺癌

2019-07-19

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

CDK4/6抑制剂哌柏西利的上市给HR+乳腺癌的治疗带来改变

2019-07-17

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

CDK4/6抑制剂哌柏西利成为HR+/HER2-晚期乳腺癌患者的新选择

2019-07-13

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

郭宇教授：HR+晚期乳腺癌CDK4/6抑制剂进展后的治疗探索

2019-06-27

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

CDK4/6抑制剂在晚期乳腺癌治疗中的研究进展

2019-06-13

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

2019ASCO：诺华的CDK4/6抑制剂Kisqali在III期晚期乳腺癌试验中提前到达终点

2019-06-05

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

CDK4/6抑制剂联合方案给HR+/HER2-乳腺癌患者带来的新希望

2019-06-02

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

苏格兰SMC批准礼来的CDK4/6抑制剂abemaciclib，用于治疗晚期或转移性乳腺癌

2019-05-16

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

CDK4/6抑制剂联合内分泌一线治疗优势人群获益良多

2019-04-22

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

王涛教授：激素受体阳性晚期乳腺癌一线优先推荐CDK4/6抑制剂联合内分泌治疗

2019-04-18

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

诺华的CDK4/6靶向性抑制剂Kisqali遭NICE拒绝，用于治疗晚期乳腺癌

2019-04-12

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

CLIN CANCER RES：PI3K和CDK4/6联合抑制治疗PIK3CA突变肺鳞状细胞癌

2018-12-21

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

徐兵河教授：CDK4/6抑制剂在乳腺癌治疗中的价值

2018-10-18

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

CDK4/6抑制剂“三兄弟”，谁领风骚

2018-10-18

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

CSCO2018大家访谈录│王晓稼教授：内分泌+CDK4/6抑制剂还是化疗

2018-09-28

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

胡夕春教授：乳腺癌治疗新突破，CDK4/6抑制剂独领风骚！

2018-06-13

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

CLIN CANCER RES：肢端黑色素瘤CDK4通路基因改变表明CDK4/6抑制可以作为靶向疗法

2017-11-25

科室
- - 订阅+
  - 更多科室
工具
服务